No :) I’m saying that the epitope the ligand binds may have bioactive analogs on other proteins in sites accessible to the ligand. This is where off-target binding mostly comes from, and it’s hard to prevent.
Contrast this with a ligand being good at “binding things in general,” ie without regard to structure. This problem is relatively easy to prevent.
It’s been more than a decade since I was at university, so it’s plausible that I’m not up to date anymore on how ligands get chosen.
Is the claim that you are making that ligands that are chosen as drug candidates these days generally don’t bind anything off-target?
No :) I’m saying that the epitope the ligand binds may have bioactive analogs on other proteins in sites accessible to the ligand. This is where off-target binding mostly comes from, and it’s hard to prevent.
Contrast this with a ligand being good at “binding things in general,” ie without regard to structure. This problem is relatively easy to prevent.